Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With Cancer
Status:
Terminated
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Placing a gene into T cells may improve the body's ability to recognize cancer
cells and build an immune response to fight cancer. Drugs used in chemotherapy, such as
cyclophosphamide and fludarabine phosphate, work in different ways to stop the growth of
tumor cells, either by killing the cells or by stopping them from dividing. Biological
therapies, such as aldesleukin, may stimulate the immune system in different ways and stop
cancer cells from growing. Giving specially treated T cells together with cyclophosphamide,
fludarabine phosphate, and aldesleukin may kill more tumor cells.
PURPOSE: This phase I clinical trial is studying the side effects and best dose of treated T
cells when given together with cyclophosphamide, fludarabine phosphate, and aldesleukin in
treating patients with cancer.